THE EFFECT OF CHEMOTHERAPY WITH FLUODARABINE/MITOXANTRONE/DEXAMETHASONE ON THE DISTRIBUTION OF SPECTRIN IN LYMPHOCYTES OF NON-HODGKIN LYMPHOMA PATIENTS

PATRYCJA DUBIELECKA¹, STANISLAW POTOCZEK², BOZENA JAZWIEC², JOANNA MILOSZEWSKA³, KAZIMIERZ KULICZKOWSKI² and ALEKSANDER F. SIKORSKI¹

¹University of Wroclaw, Institute of Biochemistry, 51-148 Wroclaw, Przybyszewskiego 63/77, ²Department of Haematology, Medical School, 50-367 Wroclaw, Pasteura 4, ³The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Cell Biology, 5, W.K. Roentgen St., Warsaw, Poland

The effect of the treatment of non-Hodgkin lymphoma patients with cytostatic regimen FMR (Fludarabine/Mitoxantrone/Dexamethasone) on the distribution of nonerythroid spectrin in peripheral lymphocytes was studied. In addition, the distribution of PKC isoforms θ, βI and βII during this treatment was tested.

We found that both in normal, peripheral, mature lymphocytes and in cells isolated from patients blood before chemotherapy the distribution of spectrin was similar: spectrin epitopes as detected with anti-nonerythroid spectrin antibodies by using immunofluorescence technique were uniformly distributed in the membrane and in the cytoplasm. After one week of FMD therapy the pattern of spectrin fluorescence in patient’s cells changed, i.e. spectrin immunofluorescence formed visible membranous aggregates, particularly visible at cell-cell surfaces of aggregated cells. Similar changes were observed when the distribution of PKCθ isoform was analysed. PKC βI and βII did not follow this change.

When lymphoid cells isolated from healthy persons or patients before FMD chemotherapy were extracted with Triton X-100 solution, most of spectrin was present in the supernatant while most of spectrin remained associated with skeletons of cells isolated from blood of patients who underwent the chemotherapy which is agreement with results observed in immunofluorescence experiments.